SNY
Sanofi
Next earnings Jul 30, 2026 · consensus $1.89 EPS, $11.4B rev
$43.16
▼ -0.62%$43.16▼ -4.80%
over 1Y
L $41.31H $49.59
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-0.6%
1W+3.3%
1M+0.8%
3M-4.9%
YTD-5.5%
1Y-4.8%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 29 analysts
Buy
Mixed signals in the latest filings.
Sanofi shows limited reported revenue.
On these fundamentals, SNY screens as SELL on the SEC figures.
Rule-based analysis, generated automatically from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 4, 2026, 10:20 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Financials · annual, by fiscal year
No income data filed.
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$103B
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield—
FCF yield—
Quality & risk
ROIC (est.)—
Free cash flow—
Total debt—
Net cash—
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY-3.5%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Recent filings
all on EDGAR ↗11-KPeriod ending 2025-12-312026-06-30open ↗11-KPeriod ending 2025-12-312026-06-30open ↗NT 11-KPeriod ending 2025-12-312026-06-30open ↗NT 11-KPeriod ending 2025-12-312026-06-30open ↗6-KPeriod ending 2026-06-242026-06-24open ↗6-KPeriod ending 2026-06-222026-06-22open ↗6-KPeriod ending 2026-06-122026-06-12open ↗6-KPeriod ending 2026-06-082026-06-08open ↗SDFiling2026-05-28open ↗6-KPeriod ending 2026-05-272026-05-27open ↗13F-HRPeriod ending 2026-03-312026-05-07open ↗SCHEDULE 13GFiling2026-05-06open ↗
Frequently asked
- Is Sanofi (SNY) a buy?
- SNY currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Mixed signals in the latest filings.
- What is Sanofi's quality score?
- SNY scores 35.03342404066821/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001121404, latest 11-K filed 2026-06-30) · EODHD · as of 7/4/2026, 2:20:33 PM.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.